Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas
NCT06863805
Summary
The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choices
Eligibility
Inclusion Criteria: * Signed written informed consent, * Adult (≥18 years) male or female patients * Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review, * well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy, * Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue, * Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA). Exclusion Criteria: * Patients already receiving previous lines of systemic therapy, * Patients not eligible for systemic therapy.
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06863805